EP3833683A4 - Polypeptid-integrin-antagonisten - Google Patents

Polypeptid-integrin-antagonisten Download PDF

Info

Publication number
EP3833683A4
EP3833683A4 EP19848229.1A EP19848229A EP3833683A4 EP 3833683 A4 EP3833683 A4 EP 3833683A4 EP 19848229 A EP19848229 A EP 19848229A EP 3833683 A4 EP3833683 A4 EP 3833683A4
Authority
EP
European Patent Office
Prior art keywords
polypeptide
integrin antagonists
integrin
antagonists
polypeptide integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19848229.1A
Other languages
English (en)
French (fr)
Other versions
EP3833683A1 (de
Inventor
M. Amin Arnaout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP3833683A1 publication Critical patent/EP3833683A1/de
Publication of EP3833683A4 publication Critical patent/EP3833683A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19848229.1A 2018-08-08 2019-08-08 Polypeptid-integrin-antagonisten Pending EP3833683A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862715860P 2018-08-08 2018-08-08
US201862757126P 2018-11-07 2018-11-07
US201862786804P 2018-12-31 2018-12-31
PCT/US2019/045762 WO2020033731A1 (en) 2018-08-08 2019-08-08 Polypeptide integrin antagonists

Publications (2)

Publication Number Publication Date
EP3833683A1 EP3833683A1 (de) 2021-06-16
EP3833683A4 true EP3833683A4 (de) 2022-09-28

Family

ID=69415156

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19847358.9A Pending EP3860977A4 (de) 2018-08-08 2019-08-08 Integrinantagonisten
EP19848229.1A Pending EP3833683A4 (de) 2018-08-08 2019-08-08 Polypeptid-integrin-antagonisten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19847358.9A Pending EP3860977A4 (de) 2018-08-08 2019-08-08 Integrinantagonisten

Country Status (5)

Country Link
US (3) US11643393B2 (de)
EP (2) EP3860977A4 (de)
AU (2) AU2019316562B2 (de)
CA (2) CA3112193A1 (de)
WO (2) WO2020033724A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10533044B2 (en) * 2014-01-06 2020-01-14 The General Hospital Corporation Integrin Antagonists
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
SG11202103484RA (en) 2018-10-30 2021-05-28 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
EP4178963A1 (de) * 2020-07-02 2023-05-17 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c!pyrazol-2-yl!indazolderivate und verwandte verbindungen als modulatoren zum spleissen von nukleinsäuren und zur behandlung proliferativer erkrankungen
US20240209034A1 (en) * 2021-04-12 2024-06-27 University Of Washington Engineering peptides for a a vb6 integrin binding and related methods of use and synthesis
CA3228660A1 (en) * 2021-08-10 2023-02-16 Texas Heart Institute Aminoaryl-integrin agonists compounds
WO2023133229A2 (en) * 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013185027A2 (en) * 2012-06-07 2013-12-12 Dcb-Usa Llc Modified fibronectin fragments or variants and uses thereof
WO2015103643A2 (en) * 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645815A (en) * 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5217994A (en) * 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
EP1054871A2 (de) 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidine und triazine als integrinantagonisten
CN107542013B (zh) * 2016-06-27 2019-06-21 一路行（北京）科技有限公司 一种臂结构及采用臂结构的道床线路施工与维护装置
MX2019000043A (es) 2016-07-05 2019-07-04 Univ Rockefeller Antagonistas de integrina de tetrahidronaftiridinpentanamida.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013185027A2 (en) * 2012-06-07 2013-12-12 Dcb-Usa Llc Modified fibronectin fragments or variants and uses thereof
WO2015103643A2 (en) * 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 10 September 2015 (2015-09-10), "Human fibronectin type III domain protein fragment, SEQ ID 71.", XP002807324, retrieved from EBI accession no. GSP:BCC05345 Database accession no. BCC05345 *
DATABASE Geneseq [online] 10 September 2015 (2015-09-10), "Human mutant fibronectin type III domain protein fragment, SEQ ID 72.", XP002807323, retrieved from EBI accession no. GSP:BCC05346 Database accession no. BCC05346 *
DATABASE Geneseq [online] 13 February 2014 (2014-02-13), "Human FNIII 10 mutant protein (CX8C), SEQ:50.", XP002807325, retrieved from EBI accession no. GSP:BBA87860 Database accession no. BBA87860 *
ESTEVEZ BRIAN ET AL: "Targeting Integrin and Integrin Signaling in Treating Thrombosis", TRANSLATIONAL SCIENCES, vol. 35, no. 1, 1 January 2015 (2015-01-01), pages 24 - 29, XP055950969, ISSN: 1079-5642, DOI: 10.1161/ATVBAHA.114.303411 *
RICHARDS J ET AL: "Engineered Fibronectin Type III Domain with a RGDWXE Sequence Binds with Enhanced Affinity and Specificity to Human @av@b3 Integrin", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 326, no. 5, 7 March 2003 (2003-03-07), pages 1475 - 1488, XP004454119, ISSN: 0022-2836, DOI: 10.1016/S0022-2836(03)00082-2 *
See also references of WO2020033731A1 *
VAN AGTHOVEN JOHANNES F ET AL: "Structural basis for pure antagonism of integrin [alpha]V[beta]3 by a high-affinity form of fibronectin", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 21, no. 4, 23 March 2014 (2014-03-23), New York, pages 1 - 20, XP055920470, ISSN: 1545-9993, Retrieved from the Internet <URL:http://www.nature.com/articles/nsmb.2797> DOI: 10.1038/nsmb.2797 *

Also Published As

Publication number Publication date
US11685717B2 (en) 2023-06-27
AU2019316562A1 (en) 2021-03-25
US20220356217A1 (en) 2022-11-10
EP3860977A1 (de) 2021-08-11
CA3112523A1 (en) 2020-02-13
US20220081398A1 (en) 2022-03-17
CA3112193A1 (en) 2020-02-13
WO2020033731A1 (en) 2020-02-13
AU2019318538A1 (en) 2021-03-25
EP3860977A4 (de) 2023-02-22
AU2019316562B2 (en) 2024-03-28
WO2020033724A1 (en) 2020-02-13
US11643393B2 (en) 2023-05-09
US20240076268A1 (en) 2024-03-07
EP3833683A1 (de) 2021-06-16

Similar Documents

Publication Publication Date Title
EP3833683A4 (de) Polypeptid-integrin-antagonisten
EP3565839A4 (de) Checkpoint-regulatorantagonisten
EP3439658A4 (de) Lösliche c5ar-antagonisten
EP3755311A4 (de) Indanamine als pd-l1-antagonisten
EP3481814A4 (de) Tetrahydronaphthyridinpentanamid-integrin-antagonisten
EP3143037A4 (de) Alpha4beta7-integrin-thioether-peptidantagonisten
ZA202101406B (en) Integrin antagonists
GB201719557D0 (en) Polypeptide
GB201905552D0 (en) Antagonists
EP3562826A4 (de) Integrinantagonisten
IL292692A (en) mrgprx2 antagonists and their uses
EP3813861A4 (de) Heparin-assoziierte polypeptide und deren verwendung
EP3768720A4 (de) Neuartiges anti-lag-3-antikörper-polypeptid
GB201819200D0 (en) Polypeptide and uses thereof
EP3747784A4 (de) Delaminierungsbehälter
EP3894441A4 (de) Rank-antagonisten und deren verwendungen
EP3858868A4 (de) Polypeptidzusammensetzung
EP3802565A4 (de) Polypeptide
EP3816186A4 (de) Pd-l1-bindende polypeptide und verwendung davon
EP3653063A4 (de) Peptid
AU2019350356A1 (en) Arginase1 polypeptides
EP3851448A4 (de) Antierythropoietinrezeptor-peptid
GB201815629D0 (en) Antagonists
EP3725884A4 (de) Zellmembranpermeable peptide
EP3744651A4 (de) Delaminierungsbehälter

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GENERAL HOSPITAL CORPORATION

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101ALI20220818BHEP

Ipc: A61P 1/16 20060101ALI20220818BHEP

Ipc: C07K 7/64 20060101ALI20220818BHEP

Ipc: C07K 14/705 20060101ALI20220818BHEP

Ipc: C07K 14/78 20060101AFI20220818BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20220825